NASDAQ:AXGN AxoGen (AXGN) Stock Price, News & Analysis $12.75 -0.17 (-1.32%) (As of 11:07 AM ET) Add Compare Share Share Today's Range$12.72▼$13.0350-Day Range$6.81▼$12.9252-Week Range$3.45▼$13.03Volume46,023 shsAverage Volume401,478 shsMarket Capitalization$557.24 millionP/E RatioN/ADividend YieldN/APrice Target$13.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get AxoGen alerts: Email Address AxoGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.8% Upside$13.80 Price TargetShort InterestHealthy4.48% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.50) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.12 out of 5 starsMedical Sector791st out of 924 stocksElectromedical Equipment Industry18th out of 21 stocks 1.5 Analyst's Opinion Consensus RatingAxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAxoGen has only been the subject of 3 research reports in the past 90 days.Read more about AxoGen's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.48% of the outstanding shares of AxoGen have been sold short.Short Interest Ratio / Days to CoverAxoGen has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in AxoGen has recently decreased by 19.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxoGen does not currently pay a dividend.Dividend GrowthAxoGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AXGN. Previous Next 3.9 News and Social Media Coverage News SentimentAxoGen has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AxoGen this week, compared to 2 articles on an average week.Search Interest5 people have searched for AXGN on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.MarketBeat Follows1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AxoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of AxoGen is held by insiders.Percentage Held by Institutions80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AxoGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AxoGen are expected to grow in the coming year, from ($0.50) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AxoGen is -25.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AxoGen is -25.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxoGen has a P/B Ratio of 5.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about AxoGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMassive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. Click here to get details on this opportunity now. About AxoGen Stock (NASDAQ:AXGN)AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Read More AXGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AXGN Stock News HeadlinesAugust 14, 2024 | finance.yahoo.comAXGN Sep 2024 15.000 call (AXGN240920C00015000)August 13, 2024 | americanbankingnews.comAxoGen (NASDAQ:AXGN) Rating Increased to Buy at StockNews.comAugust 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. August 11, 2024 | nz.finance.yahoo.comAxoGen Second Quarter 2024 Earnings: Beats ExpectationsAugust 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for AxoGen: Strong Q2 Performance and Strategic Leadership Amidst Market Growth PotentialAugust 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for AxoGen Amid Strong Q2 Performance and Positive Growth OutlookAugust 9, 2024 | seekingalpha.comApple, Inc. (AXGN) Q2 2024 Earnings Call TranscriptAugust 8, 2024 | markets.businessinsider.comAxogen, Inc. Reports Second Quarter 2024 Financial ResultsAugust 22, 2024 | Crypto 101 Media (Ad)Massive Crypto Selloff = Historic OpportunityStocks recently suffered the worst 1-day loss since 2022… Cryptos got hammered as well…But here's the fact everyone is missing… As of this writing, Bitcoin is still up 28% year to date…And it's up 84% in the last year. August 8, 2024 | globenewswire.comAxogen, Inc. Announces New Leadership AppointmentsAugust 7, 2024 | markets.businessinsider.comAxoGen earnings preview: what to expectAugust 1, 2024 | nz.finance.yahoo.comAxoGen, Inc. (0HKD.L)July 23, 2024 | globenewswire.comAxogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024July 20, 2024 | sg.finance.yahoo.comAxoGen, Inc. (AXGN) stock historical prices & data – Yahoo FinanceJuly 1, 2024 | globenewswire.comCompany Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)June 24, 2024 | globenewswire.comAxogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™May 18, 2024 | ca.finance.yahoo.comALGN May 2024 350.000 callMay 16, 2024 | finance.yahoo.comAxogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®See More Headlines Receive AXGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2021Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:AXGN CUSIPN/A CIK805928 Webwww.axogeninc.com Phone(386) 462-6800Fax386-462-6801Employees450Year FoundedN/APrice Target and Rating Average Stock Price Target$13.80 High Stock Price Target$20.00 Low Stock Price Target$9.00 Potential Upside/Downside+6.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,720,000.00 Net Margins-12.99% Pretax Margin-12.99% Return on Equity-22.18% Return on Assets-11.06% Debt Debt-to-Equity Ratio0.72 Current Ratio3.43 Quick Ratio2.23 Sales & Book Value Annual Sales$173.48 million Price / Sales3.25 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book5.82Miscellaneous Outstanding Shares43,705,000Free Float40,646,000Market Cap$564.67 million OptionableOptionable Beta1.11 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMs. Karen Zaderej (Age 62)Chairman, President & CEO Comp: $1.49MMr. Erick DeVinney (Age 48)Chief Innovation Officer Comp: $557.9kMr. Harold D. TamayoVice President of Finance & Investor RelationsMr. Marc A. Began (Age 56)Executive VP, General Counsel & Chief Compliance Officer Ms. Doris QuackenbushVice President of SalesMr. Jens Schroeder KempChief Marketing OfficerDr. Ivica Ducic M.D.Ph.D., Chief Medical OfficerMore ExecutivesKey CompetitorsCuteraNASDAQ:CUTRNatus MedicalNASDAQ:NTUSIntegra LifeSciencesNASDAQ:IARTCONMEDNYSE:CNMDRxSightNASDAQ:RXSTView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCSold 1,523,508 shares on 8/16/2024Ownership: 0.070%Millennium Management LLCSold 634,391 shares on 8/15/2024Ownership: 1.560%First Light Asset Management LLCBought 2,578,147 shares on 8/14/2024Ownership: 7.651%Cubist Systematic Strategies LLCSold 29,134 shares on 8/14/2024Ownership: 0.206%Squarepoint Ops LLCBought 39,624 shares on 8/14/2024Ownership: 0.139%View All Insider TransactionsView All Institutional Transactions AXGN Stock Analysis - Frequently Asked Questions How have AXGN shares performed this year? AxoGen's stock was trading at $6.83 at the beginning of the year. Since then, AXGN stock has increased by 87.4% and is now trading at $12.80. View the best growth stocks for 2024 here. How were AxoGen's earnings last quarter? AxoGen, Inc. (NASDAQ:AXGN) posted its quarterly earnings results on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to analyst estimates of $34.65 million. AxoGen had a negative net margin of 12.99% and a negative trailing twelve-month return on equity of 22.18%. What is Karen Zaderej's approval rating as AxoGen's CEO? 19 employees have rated AxoGen Chief Executive Officer Karen Zaderej on Glassdoor.com. Karen Zaderej has an approval rating of 100% among the company's employees. This puts Karen Zaderej in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at AxoGen to a friend. Who are AxoGen's major shareholders? Top institutional shareholders of AxoGen include First Light Asset Management LLC (7.65%), Assenagon Asset Management S.A. (3.00%), Divisadero Street Capital Management LP (1.57%) and Millennium Management LLC (1.56%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan and William P Mr Burke. View institutional ownership trends. How do I buy shares of AxoGen? Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AxoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include Advanced Micro Devices (AMD), Bank of America (BAC), Intelsat (I), Intel (INTC), Micron Technology (MU), Xilinx (XLNX) and Corbus Pharmaceuticals (CRBP). This page (NASDAQ:AXGN) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredMillionaire Investor Warns: “Brace for Apple Collapse”Apple stock has quadrupled over the past five years. But now even Warren Buffett is pulling the plug. The O...Stansberry Research | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AxoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AxoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AXGN Stock Alerts